Endothelial Microparticles and Platelet and Leukocyte Activation in Patients With the Metabolic Syndrome

Arteaga, Roque B.; Chirinos, Julio A.; Soriano, Andres O.; Jy, Wenche; Horstman, Lawrence L.; Jiménez, Joaquín J.; Mendez, Armando J.; Ferreira, Alexandre; Marchena, Eduardo de; Ahn, Yeon S.

doi:10.1016/j.amjcard.2006.01.054

Cited by 148 publications

(123 citation statements)

References 28 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…In fact, every risk factor and/or clinical symptom associated with the metabolic syndrome including insulin resistance (Anfossi et al, 2003), vascular inflammation (Esposito et al, 2004), dyslipidemia (Arruzazabala et al, 2002), hypertension (Serebruany et al, 2006), and obesity (Anfossi et al, 2004) may per se cause platelet activation. As a combination of the above-mentioned features, the metabolic syndrome obviously represents a high-risk thrombophilic state because of the activation of primary platelet hemostasis (Arteaga et al, 2006;Jesri et al, 2005), hypercoagulation (Nieuwdorp et al, 2005), and impaired fibrinolysis (Trost et al, 2006). The present data are indirectly in agreement with the concept of platelet hyperactivity in patients with the metabolic syndrome based on the fact that it takes higher doses of ESC to exhibit antiplatelet efficacy in these patients than in normal volunteers.…”

Section: Discussionsupporting

confidence: 80%

Antiplatelet Properties of Escitalopram in Patients with the Metabolic Syndrome: A Dose-Ranging In Vitro Study

Atar

Malinin

Pokov

et al. 2007

Neuropsychopharmacol

View full text Add to dashboard Cite

There is an increasing body of evidence suggesting that selective serotonin reuptake inhibitors exhibit clinical benefit beyond treating depression, by simultaneously inhibiting platelet activity. We recently demonstrated that escitalopram (ESC), but not its major metabolites, inhibits multiple platelet biomarkers in healthy volunteers. Considering that the metabolic syndrome represents one of the major risk factors for vascular disease, we here determined how ESC affects platelet activity in such patients. We assessed the in vitro effects of preincubation with escalating (50-200 nM/l) concentrations of ESC on platelet aggregation, expression of major surface receptors by flow cytometry, and quantitatively by platelet function analyzers. Blood samples were obtained from 20 aspirin-naïve patients with documented metabolic syndrome. Pretreatment of blood samples with medium (150 nM/l), or high (200 nM/l) doses of ESC resulted in a significant inhibition of platelet aggregation induced by ADP (p ¼ 0.007) and by collagen (p ¼ 0.004). Surface platelet expression of GPIb (CD42, p ¼ 0.03), LAMP-3 (CD63, p ¼ 0.04), and GP37 (CD165, p ¼ 0.03) was decreased in the ESC-pretreated samples. Closure time by the PFA-100 analyzer was prolonged after the 200 nM/l dose (p ¼ 0.02), indicating platelet inhibition under high shear conditions. On the other hand, the lowest tested concentration of ESC (50 nM/l) did not affect platelet activity in these patients. The in vitro antiplatelet characteristics of ESC in patients with the metabolic syndrome are similar to those in healthy volunteers. However, higher ESC doses are required to induce equally potent platelet inhibition. These data justify prospective ex vivo studies with the highest therapeutic dose to determine the potential clinical advantage of ESC in high-risk patients with vascular disease.

show abstract

Section: Discussionsupporting

confidence: 80%

Antiplatelet Properties of Escitalopram in Patients with the Metabolic Syndrome: A Dose-Ranging In Vitro Study

Atar

Malinin

Pokov

et al. 2007

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…intercellular adhesion molecule-1, P-selectin, and E-selectin) than those without the syndrome (142)(143)(144)(145). Moreover, increased endothelial cell microparticles (EMP) release, platelet and leukocyte hyperactivation, increased binding of both EMPs and platelets to leukocytes are also shown in patients with the metabolic syndrome (133,146). Conversely, plasma levels of anticoagulant protein C, protein S, and antithrombin appear to be decreased in these patients (122)(123)(124).…”

Section: Hypercoagulability and Hypofibrinolysismentioning

confidence: 99%

Hemostatic abnormalities in endocrine and metabolic disorders

Franchini¹,

Lippi²,

Manzato³

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

The hemostatic balance is a complex system where the delicate equilibrium is regulated by several factors, including hormones. This review summarizes current knowledge of the effects of most frequent endocrine and metabolic diseases (such as hypothyroidism, hyperthyroidism, Cushing's syndrome, GH-related pituitary dysfunctions, pituitary prolactin-producing adenomas, polycystic ovary syndrome, primary hyperparathyroidism, and metabolic syndrome) on coagulation and fibrinolysis. Overt hypothyroidism appears to be associated with a bleeding tendency, whereas all other endocrine diseases appear to be associated with a thrombotic tendency. Globally, the disorders of coagulation and fibrinolysis usually range from mild to moderate, and, rarely, to severe laboratory abnormalities (for example, bleeding diathesis in overt hypothyroidism mainly due to an acquired von Willebrand's disease type 1). Further larger and high-quality studies are needed to provide more definitive information on the effects of endocrine disorders on coagulation and fibrinolysis.

show abstract

“…Previous studies have also addressed microparticles in patients with MetS. Arteaga et al [71] reported endothelial-cell microparticle release, platelet and leukocyte activation and increased binding of microparticles from endothelial cells and platelets to leukocytes in patients with the MetS, whereas Ueba et al [72] reported that platelet microparticle levels were predictive of MetS. Chironi and colleagues [73] showed that…”

Section: Metabolic Syndrome (Mets)mentioning

confidence: 99%

Microparticles as Biomarkers of Vascular Dysfunction in Metabolic Syndrome and its Individual Components

Agouni¹,

Andriantsitohaina²,

Martinez

2014

CVP

View full text Add to dashboard Cite

Endothelial Microparticles and Platelet and Leukocyte Activation in Patients With the Metabolic Syndrome

Cited by 148 publications

References 28 publications

Antiplatelet Properties of Escitalopram in Patients with the Metabolic Syndrome: A Dose-Ranging In Vitro Study

Antiplatelet Properties of Escitalopram in Patients with the Metabolic Syndrome: A Dose-Ranging In Vitro Study

Hemostatic abnormalities in endocrine and metabolic disorders

Microparticles as Biomarkers of Vascular Dysfunction in Metabolic Syndrome and its Individual Components

Contact Info

Product

Resources

About